DaVita (NYSE:DVA) Updates FY 2025 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 10.200-11.300 for the period, compared to the consensus earnings per share estimate of 11.440. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Separately, Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, DaVita currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Stock Performance

Shares of DVA traded up $5.45 on Thursday, reaching $177.45. 1,008,829 shares of the stock traded hands, compared to its average volume of 577,985. The firm has a market cap of $14.55 billion, a price-to-earnings ratio of 19.14, a P/E/G ratio of 0.84 and a beta of 0.94. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita has a 12 month low of $118.56 and a 12 month high of $179.60. The stock’s 50-day moving average price is $161.15 and its 200-day moving average price is $157.11.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 88.18% and a net margin of 6.53%. Equities analysts forecast that DaVita will post 9.71 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.